--- schema_version: "secwatch.filing_event.v1" accession: "0001140361-26-024407" form_type: "8-K" ticker: "IONS" cik: "0000874015" company_name: "IONIS PHARMACEUTICALS INC" filed_at: "2026-06-08T16:49:43+00:00" generated_at: "2026-06-08T16:51:10.804287+00:00" event_type: "leadership" sentiment: "neutral" materiality_score: 0.4 calibrated_materiality_score: 0.4 confidence: "high" source: SEC EDGAR --- # Ionis appoints Ludwig Hantson to board; shareholders approve equity plan amendments ## Summary - Ludwig Hantson, former Alexion CEO, appointed to board effective June 4, 2026. - Peter Reikes also appointed to board; directors Joseph Wender and Lynne Parshall retired. - Shareholders approved increase of 2011 equity plan by 9.5M shares to 52M total. - ESPP amended to add 750k shares and remove termination date; Ernst & Young ratified as auditor. - Advisory vote on executive compensation passed with ~135.5M votes for. ## SEC filing metadata - accession: 0001140361-26-024407 - form_type: 8-K - ticker: IONS - cik: 0000874015 - company_name: IONIS PHARMACEUTICALS INC - filed_at: 2026-06-08T16:49:43+00:00 - event_type: leadership - sentiment: neutral - materiality_score: 0.4 - calibrated_materiality_score: 0.4 - confidence: high - sec_items: 5.02, 7.01, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036126024407/0001140361-26-024407-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036126024407/ef20075669_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001140361-26-024407 - JSON: https://secwatch.observer/filing/0001140361-26-024407.json - Plain text: https://secwatch.observer/filing/0001140361-26-024407.txt ## Key facts - Executive change Ludwig N. Hantson was appointed as member of the Board of Directors at IONIS PHARMACEUTICALS INC. - Action: appointed - Role: member of the Board of Directors source text: appointed Ludwig N. Hantson as a member of the Company’s Board effective June 4, 2026 evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036126024407/0001140361-26-024407-index.htm - Executive change Peter N. Reikes was appointed as member of the Board of Directors at IONIS PHARMACEUTICALS INC. - Action: appointed - Role: member of the Board of Directors source text: the Company also appointed Peter N. Reikes as a member of the Company’s Board effective June 4, 2026 evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036126024407/0001140361-26-024407-index.htm - Shareholder Votes IONIS PHARMACEUTICALS INC shareholders approved Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year at the 2026-06-04 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 5: Ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year: FOR AGAINST ABSTAIN BROKER NON-VOTES 148,893,646 4,000,539 150,525 0 The Company’s stockholders approved the foregoing proposal. evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036126024407/0001140361-26-024407-index.htm - Shareholder Votes IONIS PHARMACEUTICALS INC shareholders approved Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares at the 2026-06-04 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 3 : Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares: FOR AGAINST ABSTAIN BROKER NON-VOTES 108,377,084 32,303,288 58,643 12,305,695 The Company’s stockholders approved the foregoing proposal. evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036126024407/0001140361-26-024407-index.htm - Shareholder Votes IONIS PHARMACEUTICALS INC shareholders approved Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the termination date of the plan at the 2026-06-04 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 4: Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the termination date of the plan: FOR AGAINST ABSTAIN BROKER NON-VOTES 140,348,001 332,204 58,810 12,305,695 The Company’s stockholders approved the foregoing proposal. evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036126024407/0001140361-26-024407-index.htm - Shareholder Votes IONIS PHARMACEUTICALS INC shareholders approved Election of directors to hold office until the 2029 Annual Meeting at the 2026-06-04 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-06-04 source text: The Company held its virtual Annual Meeting of Stockholders on June 4, 2026. The stockholders considered five proposals, each of which is described in more detail in the Company’s definitive proxy statement dated April 23, 2026. Proposal 1: Election of directors to hold office until the 2029 Annual Meeting: FOR AGAINST ABSTAIN BROKER NON-VOTES Spencer R. Berthelsen 119,824,353 20,816,547 98,115 12,305,695 Joan E. Herman 135,599,646 5,076,895 62,474 12,305,695 The Company’s stockholders elected the foregoing candidates by affirmative votes by a majority of the votes of the shares represented in person or by proxy at the meeting and entitled to vote in the election of directors. evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036126024407/0001140361-26-024407-index.htm - Shareholder Votes IONIS PHARMACEUTICALS INC shareholders approved An advisory vote on the compensation paid to the Company's executive officers at the 2026-06-04 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 2 : An advisory vote on the compensation paid to the Company’s executive officers, including the following resolution: “RESOLVED, that Ionis’ stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as disclosed in this Proxy Statement for the 2026 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission.” FOR AGAINST ABSTAIN BROKER NON-VOTES 135,537,973 5,088,105 112,937 12,305,695 The Company’s stockholders approved the foregoing proposal. evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036126024407/0001140361-26-024407-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.